% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jan 4, 2013 10:44 PM Flag

    Emerging Treatments in NSCLC


    Dr Mark Kris of MSK in OncLive today 1/4/12, on Cabo in RET-driven NSCLC.

    "Another group of patients are those with RET fusion genes. Barely 1 year ago, this abnormality was discovered, and already there were reports at ESMO this year that the drug cabozantinib can effectively treat these patients. "

    Interesting overall commentary on the use of TKI's in NSCLC...and some interesting thoughts wrt the recently cancelled tivantinib trial. If I read Dr Kris correctly, it is his belief that the P3 MARQUEE trial wasn't clearly supported by earlier P2 data, and perhaps the late stage trial should not even have been initiated.

    Though not mentioned specifically in this article, Cabo's proven effectiveness in erlotinib resistant patient pops make NSCLC another indication to watch for in future NCCN recommendations where RET and EGFR are the diagnosed drivers of tumor growth.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.84+0.20(+2.31%)10:29 AMEDT